YOLFTbeta
Adagene Inc

Adagene Inc

ADAG · NASDAQ · Healthcare / Biotechnology

1.71USD-0.29 (-14.50%)

Price History

Full chart

Market Stats

Previous Close2.00
Open1.98
Day Range1.70 – 1.98
52-Week Range1.30 – 4.85
Volume152.06K
Market Cap200.09M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.38
Dividend Yield0.00%
Beta0.56
50-Day Avg3.63
200-Day Avg3.31

About

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Peter P. Luo Ph.D.
  • Employees128
  • HeadquartersBuilding C14, Suzhou, China, 215123, USA
  • Websitehttps://www.adagene.com

Leadership

  • Dr. Peter P. Luo Ph.D.Co- Founder, Chairman, CEO and President of R&D · b. 1966
  • Mr. Man Kin Tam M.B.A.CFO & Director · b. 1977
  • Ms. Ling ZhouExecutive Director & Head of Human Resources
  • Dr. Qinghai Zhao Ph.D.Chief Manufacturing Officer · b. 1961
  • Mr. Mickael Chane-DuChief Strategy Officer
  • Ms. Chunfang GuExecutive Director of Finance
  • Ms. Yan Li M.B.A.Senior Vice President of Bioinformatics & Information Technology · b. 1975
  • Ms. Xiaohong SheSenior VP & Head of Clinical Operations · b. 1967
  • Dr. Guizhong Liu Ph.D.Senior Vice President of Early Drug Discovery · b. 1971
  • Mr. Alexander GoergenVP & Head of Business Development · b. 1987

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.51M480.00K480.00K10.18M9.29M18.11M103.20K7.67M
Growth (%)--68.24%0.00%+2019.85%-8.67%+94.90%-99.43%+7332.76%
Cost of Revenue------926.25K582.64K
Gross Profit1.51M480.00K480.00K10.18M9.29M18.11M-823.04K7.67M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%-797.49%100.00%
Operating Expense18.85M19.65M19.65M82.54M93.21M41.83M35.13M29.11M
Operating Income-17.33M-19.17M-19.17M-72.36M-83.92M-23.72M-35.95M-21.44M
Operating Margin-1147.09%-3993.68%-3993.68%-711.18%-903.08%-130.97%-34835.42%-279.48%
EBITDA-14.27M-15.48M-41.34M-69.99M-77.39M-14.95M-31.66M-16.85M
EBITDA Margin-944.04%-3224.49%-8611.81%-687.82%-832.80%-82.55%-30680.54%-219.72%
Net Income-14.72M-17.29M-16.44M-73.18M-79.97M-18.95M-33.42M-17.61M
Net Income Margin-974.03%-3602.89%-3424.06%-719.18%-860.59%-104.61%-32386.45%-229.56%
R&D16.08M16.21M16.21M68.10M81.34M36.64M28.78M22.03M
R&D as % of Total Revenue1064.11%3377.45%3377.45%669.26%875.30%202.30%27887.88%287.24%
Interest Expense91.08K138.10K202.16K363.76K693.32K1.11M851.87K463.13K
Interest Expense % of Total Revenue6.03%28.77%42.12%3.57%7.46%6.12%825.43%6.04%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets54.42M105.89M84.26M189.51M152.40M115.73M89.27M78.26M
Total Liabilities95.44M162.90M173.65M32.95M69.31M45.17M38.74M42.91M
Total Equity-41.03M-57.01M-89.39M156.56M83.09M70.56M50.52M35.35M
Cash16.06M92.53M75.15M174.39M143.76M109.93M85.19M74.52M
Total Debt2.33M2.56M7.98M7.49M27.97M22.31M18.49M6.26M
Net Debt-13.73M-89.98M-67.17M-166.90M-115.79M-87.63M-66.70M-68.26M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.26M-18.15M-28.53M-43.41M-48.61M-28.45M-29.70M-15.66M
Investing Cash Flow-29.51M24.86M7.07M-2.51M-686.05K-77.36K1.11M476.80K
Financing Cash Flow51.06M69.69M4.44M145.36M17.82M-5.37M3.77M4.45M
Capital Expenditure514.70K151.83K935.20K2.51M690.94K85.01K33.58K17.05K
Free Cash Flow-14.78M-18.31M-29.46M-45.92M-49.30M-28.54M-29.73M-15.67M
Dividends Paid---4.61M322.83K---
FCF to OCF103.61%100.84%103.28%105.78%101.42%100.30%100.11%100.11%
Dividend Paid to FCF----10.04%-0.65%---

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 31, 2021Jun 2, 2021Aug 25, 2021Dec 1, 2021Mar 31, 2022Apr 25, 2022Aug 30, 2022Nov 3, 2022Mar 28, 2023Apr 28, 2023Aug 31, 2023Nov 29, 2023Mar 29, 2024May 29, 2024Jul 25, 2024Nov 27, 2024Mar 24, 2025May 28, 2025Aug 12, 2025Dec 3, 2025Apr 1, 2026Jun 30, 2026
EPS Estimate0.000.000.000.000.000.000.00-0.40-0.61-0.44-0.27-0.67-0.68-0.65-0.36-0.40-0.36-0.93-0.42-0.270.00-0.260.00-0.47-0.17-0.33-0.18-0.21-0.19
EPS Actual-0.30-0.30-0.39-0.39-0.72-0.72-0.94-0.64-0.61-0.32-0.27-0.47-0.25-0.77-0.36-1.55-0.15-1.48-0.42-0.270.00-0.280.00-0.29-0.17-0.230.000.00-
Surprise--------60.00%0.00%27.27%0.00%29.85%63.24%-18.46%0.00%-287.50%58.33%-59.14%0.00%0.00%--9.62%-38.30%0.00%30.30%100.00%100.00%-
Timing-------Pre-market-After-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours-----------

Key Statistics & Ratios

Market Cap200.09M
Enterprise Value76.25M
Trailing P/E0.00
Forward P/E0.00
Price / Sales21.54
Price / Book2.21
EPS-0.38
Book Value1.33
Revenue (TTM)9.29M
Gross Profit (TTM)9.29M
EBITDA-21.95M
Profit Margin-220.77%
Operating Margin-1023.92%
Return on Equity-28.50%
Return on Assets-13.95%
Shares Outstanding67.14M
Shares Float42.11M
Beta0.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 9.91
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
36.00%
Insiders
11.36%
Retail / Other
52.64%

Top Institutional Holders

  • HSG Holding Ltd
    1.34M2.00%
  • Squadron Capital Management LLC
    1.25M1.86%
  • Ameriprise Financial Inc
    607.90K0.91%
  • Citadel Advisors Llc
    506.93K0.76%
  • Exome Asset Management LLC
    488.29K0.73%
  • Mill Creek Capital Advisors LLC
    199.61K0.30%
  • Quadrature Capital Limited
    80.49K0.12%
  • Morgan Stanley - Brokerage Accounts
    66.15K0.10%
  • Amvescap Plc.
    47.12K0.07%
  • SmartHarvest Portfolios, LLC
    41.69K0.06%
  • Kamunting Street Cap Management, L.p.
    38.07K0.06%
  • Persistent Asset Partners Limited
    35.13K0.05%
  • Dauntless Investment Group, LLC
    34.77K0.05%
  • Renaissance Technologies Corp
    34.53K0.05%
  • Jane Street Group LLC
    30.43K0.05%
  • Alyeska Investment Group, L.P.
    20.71K0.03%
  • Royal Bank of Canada
    16.85K0.03%

Top Fund Holders

  • Fullgoal Glb Healt Life Alloc(QDII)USD
    150.00K0.22%
  • Invesco Golden Dragon China ETF
    41.73K0.06%
  • Fidelity Nasdaq Composite Index
    38.35K0.06%